Mexico Develops New Method for Analyzing E-Cigarette Aerosol

Dec.27.2022
Mexico Develops New Method for Analyzing E-Cigarette Aerosol
Mexico has developed a new method to analyze aerosols in e-cigarettes that could interest other health organizations.

In late October, a Mexican health regulatory agency announced that its scientists have developed a new method for analyzing the aerosol in electronic cigarettes (Electronic Nicotine Delivery Systems, ENDS). Alejandro Svarch, head of Cofepris, stated that the final results of using this new method to analyze ENDS products will be published in scientific journals in the coming months. Svarch added that Mexico's "cutting-edge method" will pique the interest of other health departments in other countries.


This situation is perplexing because researchers have been able to evaluate the aerosols in ENDS products for some time. Additionally, Mexico banned the sale of ENDS products in June. This has left many in the vaping industry wondering how the country can defend its ban on ENDS when it now claims it lacks the ability to test product safety.


Every country that regulates electronic cigarette products requires testing for various elements, such as harmful and potentially harmful constituents (HPHC) and heavy metals. According to Kim Hesse, Vice President of Sales and Marketing for the regulatory science consulting firm McKinney, researchers have been using aerosol testing methods for years to evaluate air quality, combustible cigarette smoke, and aerosols in inhalable medical products. ENDS aerosol testing has been around for nearly 15 years.


According to Hesse, it is important to test ENDS products to ensure that the public is not inhaling potential harmful compounds, such as heavy metals or diacetyl. By testing these products, the industry can ensure consistency and provide regulatory agencies, such as the US Food and Drug Administration and other government entities, with the data needed to evaluate ENDS products.


Hesse responded to questions regarding ENDS testing in the tobacco publication Vapor Voice. Below is a transcript of the interview.


Vapor Voice: What type of experience do you have in testing tobacco and ENDS products?


Hesse stated that they have published several scientific articles demonstrating their knowledge, skills, and experience in testing tobacco and ENDS products. For example, they recently published an article highlighting the importance of traditional toxicology indicators in generating and characterizing ENDS aerosols.


Vapor Voice: What are the differences between testing the vapor from electronic cigarettes and testing combustible tobacco cigarettes?


Hesse says that it depends on the situation. Testing combustible cigarette smoke that contains both particles and gas is more challenging than simply testing ENDS aerosols.


However, when considering product variability, ENDS products present many challenges that cigarettes do not. ENDS products come in a variety of shapes and sizes, some with round mouthpieces and others with square ones. This alone presents a challenge in connecting the device to smoking equipment, as the adapter is typically round. Some devices also have buttons, with all of these buttons located in different places. Some e-cigarettes have a push-button mechanism that does not match with various button shapes and locations. In contrast, cigarettes are uniform in size, and 20 cigarettes can easily be ignited with a standardized lighter built into smoking machines.


After conducting tests, it was found that combustible cigarettes were tested alongside a fixed amount of cream puffs, while electronic cigarettes were only tested with a set number of cream puffs. Once all aerosol or smoke was collected, the remaining testing was carried out in essentially the same manner for both aerosol and smoke. While electronic cigarettes and combustible cigarettes were both tested using the same equipment, there were slight differences in methodology (such as the number of cream puffs used and the spacing between the cream puffs and volume).


Vapor Voice: How do companies determine which standards to use and ensure there are no discrepancies in testing? Translation: Vapor Voice inquires about the process companies employ to determine which standards of testing to utilize and how they ensure there are no inconsistencies.


Hesse stated that both combustible cigarettes and ENDS products have standardized Coresta environmental (ISO) testing procedures. The electronic cigarette method used by Health Canada was determined by the manufacturer's scientists and established based on the limitations of the equipment (some devices have puff duration limits).


Due to the marked reduction in ingredients in electronic cigarettes, the analytical methods between combustible cigarettes and electronic cigarette products may also differ slightly. In the analysis of electronic cigarettes, the calibration curve is usually much lower. Other variations relate to the angle of testing for electronic cigarette devices. The testing angle of the device is based on models such as tanks and wicks.


Vapor Voice: Are there many challenges in testing electronic cigarettes? How can these difficulties be overcome?


Hesse emphasized the need to share data with the FDA, even if it is not favorable. Some companies only test their products and send reports to the FDA without ensuring if the data supports their products, in order to protect public health.


There is always room for improvement. We found that most laboratories are working hard to improve their methods. As previously stated, the variety of sizes and shapes of ENDS devices pose a challenge. The lack of standardized testing methods for all HPHC and variability among labs present opportunities for improvement.


Vapor Voice: What is the accuracy of the testing methods and results?


Hesse stated that current analysis methods are capable of detecting chemicals at extremely low levels. However, the levels at which chemicals are typically detected do not pose a risk to human health. Some public health officials may report on chemical levels detected, rather than reporting on levels of harmful chemicals, which can result in public panic and have a negative impact on efforts to reduce harm.


Coresta has a highly effective working group focused on testing and analyzing ENDS. We should prioritize encouraging more companies and laboratories to actively participate in research aimed at simplifying and reducing variability in current methods.


A standardized field should involve creating a reference ENDS device that can be used with any remaining e-liquids - similar to the reference cigarette (1R6F) used to compare combustible cigarette data generated in different laboratories.


Vapor Voice: Based on your test results, would you say that e-cigarettes pose a lower risk compared to combustible smoking?


Hesse stated that this is not about him personally. He reported that Brian King, director of the Center for Tobacco Products at the US Food and Drug Administration (FDA), recently stated in the media that he understands the risks of e-cigarettes to be “significantly reduced” compared to combustible tobacco products. King acknowledged that the risks associated with tobacco products are a continuum and that e-cigarettes fit within that continuum. During the recent GTNF 2022 conference Hesse attended, King also mentioned that certain e-cigarette products have lower risks than combustible tobacco and that this is an important part of FDA dialogue. The FDA recognizes that e-cigarettes have lesser harm than combustible tobacco, which is significant.


Vapor Voice: Do you have any advice for companies looking to test their products?


Hesse advised that sending samples to a laboratory without understanding the testing requirements or how to interpret the data is a waste of money. It is important to work with a group of trustworthy scientists who can guide the process of generating scientific data.


Here are some suggestions: Ensure that the laboratory you choose is ISO 17025 accredited. It is recommended to use an FDA-recognized laboratory. This will improve the data review process and may prevent data submission rejection due to insufficient laboratory integrity. When selecting a laboratory, make sure they have submitted a Tobacco Product Master File (TPMF) to the FDA and have validated their methods, with the validation report included in their TPMF.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Major U.S.  Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
Major U.S. Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
New York vape distributor Ecto World, which operates as Demand Vape, hired political consultant Roger Stone to lobby the Executive Office of the President on regulation of vaping and related products while facing state enforcement and multiple lawsuits. Public lobbying disclosures show that Ecto World paid at least $300,000 for the work through June 30, 2026. Separately, New York State announced in March that more than 28,500 pounds of vaping products tied to the company had been seized, while New York City and the state have pursued legal or enforcement actions. Public records do not show that the lobbying directly changed any specific regulatory or enforcement outcome.
Sep.08
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
Australia-China Operation Dismantles Tobacco Smuggling Network: 112 Containers, 60 Arrests and A$92 Million in Illicit Tobacco
Australia-China Operation Dismantles Tobacco Smuggling Network: 112 Containers, 60 Arrests and A$92 Million in Illicit Tobacco
According to The Maritime Executive on August 19, 2026, the Australian Border Force (ABF) and China’s Anti-Smuggling Bureau of General Administration of China Customs worked together to dismantle an international illicit tobacco smuggling network targeting Australia. According to information released by ABF on August 20, sustained information sharing and cooperation led to investigations into 112 shipping containers, with 91 found to contain illicit tobacco. Authorities seized more than 60 million cigarettes and 60 kilograms of loose-leaf tobacco, representing more than A$92 million in unpaid duties. More than 60 people suspected of involvement in the network were arrested in China.
Aug.20
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22